SecureTech Completes Share Reduction Program, Achieves Goal of 17 Million Outstanding Shares
ByAinvest
Monday, Jan 12, 2026 8:32 am ET1min read
MGX--
Metagenomi Therapeutics, formerly Metagenomi, has completed its corporate name change to reflect its focus on driving forward its lead program in hemophilia A and other programs. The company has achieved several milestones, including a pre-IND meeting for MGX-001, which demonstrated curative FVIII activity in non-human primates. MGX-001 is on track for IND/CTA submissions in 4Q 2026, and the company anticipates a cash runway through 4Q 2027.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet